There has been a prolonged focus in the pharmaceutical industry on the development of AMPK-activating drugs for the treatment of metabolic disorders such as Type 2 diabetes and non-alcoholic fatty liver disease. Here, PRKAA2 is linked to metabolic dysfunction-associated steatotic liver disease.